Amgen 4Q Revenues: $4.0 billion (+3%) 4Q Earnings: $934.0 million (-9%) FY Revenues: $15.6 billion (+4%) FY Earnings: $3.7 billion (-20%)    Comments: U.S. product sales were up 5% to $3.0 billion in the quarter, and up 4% to $11.7 million for the year. International product sales in the quarter were $900 million (+1%), and $3.6 million for the year (+5%). Combined Neulasta and Neupogen sales were $1.3 billion (+7%) in the quarter and up 8% to $5.2 billion for the year. Enbrel sales were $9...